Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

TRACERx NSCLC - Whole exome multiregion sequencing data

ABSTRACT: TRACERx (TRAcking Cancer Evolution through therapy (Rx)) is a prospective cohort study designed to investigate intratumor heterogeneity (ITH) in relation to clinical outcome, and to determine the clonal nature of driver events and evolutionary processes in early stage non-small cell lung cancer (NSCLC).

PROVIDER: EGAS00001006494 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Similar Datasets

RRBS data from TRACERx non-small cell lung cancer (NSCLC) tumours and matched normal adjacent tissue.

| EGAS00001006523 | EGA

TRACERx 100: RNAseq data from the first 100 TRACERx tumours

| EGAS00001003458 | EGA

Multi-region RNA sequencing of tumour regions and tumour-adjacent normal lung tissue

| EGAS00001006517 | EGA

8a537b1e-3937-467b-b258-8ed4ddae6550 - samples

Project description:RRBS data from TRACERx non-small cell lung cancer (NSCLC) tumours and matched normal adjacent tissue. TRACERx (TRAcking Cancer Evolution through therapy (Rx)) is a prospective cohort study designed to investigate intratumor heterogeneity (ITH) in relation to clinical outcome, and to determine the clonal nature of driver events and evolutionary processes in early stage non-small cell lung cancer (NSCLC).

| EGAD00001009707 | EGA

TRACERx 100: RRBS data from a subset of the first 100 TRACERx tumours

Project description:TRACERx (TRAcking Cancer Evolution through therapy (Rx)) is a prospective cohort study designed to investigate intratumor heterogeneity (ITH) in relation to clinical outcome, and to determine the clonal nature of driver events and evolutionary processes in early stage non-small cell lung cancer (NSCLC). This study looks at multi-region RRBS data from the TRACERx100 cohort selected for quantity of material available and high tumour purity. RRBS data was collected for 122 tumour regions across 36 patients each with matched normal. A subset of this cohort was used in a sister study looking at tumour neo-antigen promoter methylation status in NSCLC (71 tumour regions across 28 patients for a total of 99 samples).

| EGAS00001003484 | EGA

TRACERx NSCLC - whole genome sequencing for ctDNA study

Project description:TRACERx NSCLC - whole genome sequencing for ctDNA study

| PRJEB72492 | ENA

WES sequencing of TRACERx NSCLC patient-derived xenograft models

Project description:WES sequencing of TRACERx NSCLC patient-derived xenograft models

| EGAS00001007364 | EGA

TRACERx 100: whole exome data of the first 100 TRACERx tumours

Project description:BACKGROUNDTRACERx (TRAcking Cancer Evolution through therapy (Rx)) is a prospective cohort study designed to investigate intratumor heterogeneity (ITH) in relation to clinical outcome, and to determine the clonal nature of driver events and evolutionary processes in early stage non-small cell lung cancer (NSCLC). METHODSMultiregion high-depth whole-exome sequencing (M-seq) was performed on 100 early stage NSCLC tumors resected prior to systemic therapy. A total of 327 tumor regions were sequenced and analyzed to define evolutionary histories, obtain a census of clonal and subclonal events, and assess the relationship between ITH and recurrence-free survival (RFS). RESULTSWidespread ITH was observed for both somatic copy number alterations (median 48% [0.03-88%]) and mutations (median 30% [0.5-93%]). Driver mutations in EGFR, MET, BRAF and TP53 were almost always clonal. However, heterogeneous driver alterations occurring later in evolution were found in over 75% of tumors and were common in PIK3CA, NF1 and genes involved in chromatin modification and DNA response and repair. Genome doubling and ongoing dynamic chromosomal instability (CIN), illustrated by mirrored subclonal allelic imbalance, were identified as causes of ITH resulting in parallel evolution of driver copy number events, including amplifications of CDK4, FOXA1, and BCL11A. Elevated copy number heterogeneity was associated with shorter RFS (HR=4.9, P=0.00044), which remained significant in a multivariate analysis.CONCLUSIONSITH mediated through CIN, rather than point mutational heterogeneity, was associated with increased risk of relapse, supporting its value as a prognostic predictor, and the need to target this high-risk phenotype.

| EGAS00001002247 | EGA

Human NSCLC DIA proteomics validation cohort 2

Project description:In this project, one NSCLC cohorts were analyzed by Data Independent Acquisition (DIA-MS). A cohort of early stage NSCLC samples (207) with the aim to demonstrate utility of MS for subtyping and treatment prediction in a clinical setting. Further, six identified NSCLC proteome subtypes were investigated in relation to cancer driver pathways and immune phenotypes based on the generated MS-data.

2021-09-13 | PXD025560 | Pride

NSG-adapted reference genome - TRACERx PDX study

Project description:NSG-adapted reference genome - TRACERx PDX study

| PRJEB65917 | ENA